Cagrilintide
Long-acting amylin analogue — dual-pathway metabolic research with GLP-1 complementarity
Chemical Identity & Specifications
| Parameter | Value | Detail |
|---|---|---|
| CAS Number | 2489551-48-6 | Long-acting acylated amylin analogue |
| Peptide Class | Amylin Analogue | Amylin receptor (AMY-R) agonist |
| Molecular Weight | ~4,543 Da | Confirmed by ESI-MS |
| Structural Feature | Fatty Acid Acylation | C20 diacid linker for albumin binding — extended half-life |
| Appearance | White to Off-White Powder | Lyophilized, sterile-filtered |
| Storage | 2–8°C | Protected from light and moisture |
Available Configurations
5mg × 10 vials
Standard research configuration
PSH-CAGRI-5MG10mg × 10 vials
Higher-dose single molecule
PSH-CAGRI-10MGCag/Sema Stack
Cagrilintide 5mg + Semaglutide 5mg × 10
PSH-CAGSEMA-5MGCustom Configuration
Custom dosing, labeling, and packaging
Custom SKUAll configurations: lyophilized powder · 10 vials/kit · ≥99% HPLC · COA included
Research Background: Amylin Physiology & Dual-Pathway Strategy
Amylin Physiology: Core Functions
| Function | Mechanism | Relevance to Cagrilintide |
|---|---|---|
| Gastric Emptying | Slows nutrient delivery to the small intestine | Long-acting acylated format extends duration of gastric delay beyond native amylin |
| Glucagon Suppression | Inhibits postprandial glucagon secretion from pancreatic α-cells | Complementary to GLP-1-mediated insulin secretion — dual control of glucose homeostasis |
| Appetite Modulation | Central signaling via area postrema (AP) neurons | Targets satiety through a distinct neural circuit from GLP-1 hypothalamic pathways |
Structural Design: Why Fatty Acid Acylation Matters
Cagrilintide incorporates a C20 fatty diacid linker conjugated to the peptide backbone — the same pharmacokinetic strategy used in semaglutide. This acylation enables reversible, high-affinity binding to serum albumin, extending the circulating half-life from minutes (native amylin) to days. The result: sustained amylin receptor activation suitable for once-weekly research protocols.
Dual-Pathway Rationale: GLP-1 + Amylin Synergy
| Pathway | GLP-1 | Amylin (via Cagrilintide) | Combined Effect |
|---|---|---|---|
| Gastric Emptying | Moderate delay via vagal afferents | Strong delay via AP → DVC pathway | Synergistic gastric retention → enhanced satiety |
| Glucose Homeostasis | ↑ Insulin, glucose-dependent | ↓ Glucagon, postprandial | Dual endocrine control: insulin up + glucagon down |
| Appetite Control | Hypothalamic POMC/CART | Area postrema (AP) neurons | Two independent central satiety circuits |
| Body Weight Impact | ~15% reduction (max doses) | ~10% reduction (monotherapy) | Non-overlapping mechanisms → potential additive effect |
Quality Specifications
| Test | Method | Specification |
|---|---|---|
| Purity | RP-HPLC, C18 column, 220nm | ≥99.0% |
| Identity | ESI-MS | MW match within ±1 Da |
| Peptide Content | Amino Acid Analysis | 80–90% (net peptide) |
| Acylation Fidelity | LC-MS | Confirmed C20 diacid conjugation |
| Water Content | Karl Fischer | ≤8% |
| Appearance | Visual | White to off-white lyophilized powder |
Full analytical documentation — COA, HPLC chromatogram, MS spectrum — available with every batch
Buyer Portfolio Strategy: Where Cagrilintide Fits
| Buyer Profile | Recommended Strategy |
|---|---|
| GLP-1 Distributor | Add Cagrilintide as premium complementary SKU alongside Semaglutide/Tirzepatide. Customers seeking enhanced appetite control will value the dual-pathway option. |
| Private-Label Brand | Launch Cag/Sema fixed-dose stack as differentiated product. Command premium pricing through innovation — not commodity competition. |
| Research Consortium | Source all metabolic molecules from single factory for protocol consistency. Cagrilintide + GLP-1 from one batch-traceable supply chain. |
| Bulk Re-seller | Offer Cagrilintide in 10mg configuration for higher-volume labs. Position as the "next thing" after Semaglutide adoption plateaus. |
Bulk Pricing
Tiered volume discounts for B2B buyers. Contact Dr. Aaron Wang for a tailored quotation based on your projected monthly volume.
| Tier | Quantity | Typical Discount |
|---|---|---|
| Tier 1 | 1–3 kits | Base price |
| Tier 2 | 4–9 kits | 10–25% off |
| Tier 3 | 10–24 kits | 25–40% off |
| Tier 4 | 25–49 kits | 40–55% off |
| Bulk | 50+ kits | Contact for quote |
Stack Pricing Note: Cag/Sema fixed-dose combination kits qualify for volume pricing based on total kit count across all configurations. Contact Dr. Aaron for a detailed quotation.
Frequently Asked Questions
How does Cagrilintide complement GLP-1 receptor agonists?
Cagrilintide targets the amylin pathway (AMY-R) via the area postrema, producing distinct effects: delayed gastric emptying, reduced postprandial glucagon, and central appetite modulation. GLP-1 agonists target GLP-1R in the hypothalamus and GI tract. Together, they engage two independent satiety and nutrient-processing pathways — this is the basis for dual-pathway research protocols.
What are the recommended storage conditions?
Store lyophilized powder at 2–8°C, protected from light and moisture. Under these conditions, stability is maintained for the shelf-life period indicated in the batch COA. Avoid repeated freeze-thaw cycles. After reconstitution, solution stability is protocol-dependent; validate within your laboratory's specific conditions.
Do you offer Cagrilintide in combination vials with GLP-1 peptides?
Yes. We manufacture custom fixed-dose combination kits — for example, Cagrilintide 5mg + Semaglutide 5mg in a single vial (SKU: PSH-CAGSEMA-5MG). Minimum order quantities apply for custom formulations. This pre-formulated stack simplifies laboratory workflows and ensures batch-to-batch consistency across both molecules.
How does Cagrilintide compare to other amylin analogues?
Cagrilintide is a long-acting acylated amylin analogue engineered for extended half-life via C20 fatty acid conjugation — the same platform strategy used for semaglutide. Compared to native amylin (t½ ~13 min) or pramlintide (t½ ~50 min), Cagrilintide's structural modifications confer significantly longer residence time, enabling once-weekly dosing in research protocols. This makes it particularly well-suited for combination protocols with once-weekly GLP-1 agonists like semaglutide.
Complementary Products
Semaglutide
GLP-1 receptor agonist — the foundational incretin mimetic for metabolic research. Pairs with Cagrilintide for dual-pathway protocols.
Tirzepatide
Dual GIP/GLP-1 agonist — enhanced efficacy profile. Pair with Cagrilintide for triple-pathway investigation.
Retatrutide
Triple GIP/GLP-1/GCGR agonist — next-generation metabolic peptide. Consider alongside Cagrilintide for comprehensive multi-pathway panels.
Cag/Sema Stack
Pre-formulated Cagrilintide 5mg + Semaglutide 5mg fixed-dose combination. Ready-to-use dual-pathway kit.
⚠️ Compliance Notice: Cagrilintide supplied by Peptides Source Hub is intended exclusively for laboratory research and in-vitro study purposes. Not for human or veterinary use. Buyers are responsible for compliance with all applicable local regulations regarding the importation, handling, and use of research peptides.
Ready to Add Cagrilintide to Your Portfolio?
Bulk pricing, COA, and dual-pathway stack configurations available. Contact Dr. Aaron Wang directly.
Dr. Aaron Wang · WhatsApp +64 20 431 0558 · Telegram @DrAaronWang · aaron@senobiocorp.com